Chronic inflammation, regardless of infectious agents, plays important roles in the development of various cancers particularly in digestive organs, including Helicobacter pylori (H. pylori)-associated gastric cancer, hepatitis C virus (HCV)-positive hepatocellular carcinoma, and colitis-associated colon cancers. Cancer development is characterized by stepwise accumulation of genetic and epigenetic alterations of various proto-oncogenes and tumor suppressor genes. During chronic inflammation, infectious agents such as H. pylori and HCV as well as intrinsic mediators of inflammatory responses, including proinflammatory cytokines and reactive oxygen and nitrogen species, can induce genetic and epigenetic changes, including point mutations, deletions, duplications, recombinations, and methylation of various tumor-related genes through various mechanisms. Furthermore, inflammation also modulates the expressions of microRNAs that influence the production of several tumor-related mRNAs or proteins. These molecular events induced by chronic inflammation work in concert to alter important pathways involved in normal cellular function, and hence accelerate inflammation-associated cancer development. Among these, recent studies highlighted an important role of activation-induced cytidine deaminase, a nucleotide-editing enzyme essential for somatic hypermutation and class-switch recombination of the immunoglobulin gene, as a genomic modulator in inflammation-associated cancer development.
Introduction
Nearly 150 years ago, Rudolf Virchow noted that inflammatory cells are present in tumor tissues and that tumors develop at sites of chronic inflammation; he suggested that chronic inflammation plays important roles in cancer development. Since then, many clinical and epidemiological studies have confirmed a strong association between inflammation and cancer 1, 2 . For instance, epidemiological studies have shown that approximately 10-15% of cancers were related to chronic infections with viruses, bacteria or parasites [3] [4] [5] [6] [7] , and moreover, that up to 25% of all cancers were associated with chronic inflammation irrespective of the presence or absence of infection [5] [6] [7] .
In inflammation-associated cancer development, in addition to infectious agents such as Helicobacter pylori (H. pylori) and hepatitis C virus (HCV), many intrinsic mediators of inflammation including proinflammatory cytokines, eicosanoids, growth factors, and reactive oxygen species (ROS) and reactive nitrogen species (RNS) exert important effects in cancer development through various mechanisms. These include enhancement of cell growth and mobility, induction of angiogenesis, and inhibition of apoptosis. However, a hallmark of cancer development is the stepwise accumulation of various genetic and epigenetic alterations of the genome. Indeed, recent genome-wide analysis of human cancer tissues revealed that a single cancer cell generally possesses approximately 100 mutations in coding regions, 10-20 of which are known as "driver genes" that contribute to cancer development [8] [9] [10] , and moreover, that there are many somatic gene rearrangements, including duplications, deletions and inversions in human cancer genomes 11, 12 . In addition to genetic alterations, recent studies have also shown that chronic inflammation enhances epigenetic changes as represented by DNA methylation 13 . It is estimated that several hundreds to thousands of genes are methylated in a cancer cell 14 , and that aberrant DNA methylation is present even in normal-appearing tissues, being involved in field cancerization 13, 15, 16 .
Digestive organs are inhabited by many microorganisms and are infiltrated by many immune cells in physiological and pathological conditions, and thus they are more or less accompanied by certain levels of inflammation. Here, we review mechanisms of how inflammation is involved in cancer development in digestive organs, particularly focusing on the role of chronic inflammation in inducing genetic and epigenetic changes.
Cancers in Digestive Organs Associated with Inflammation
Many cancers arise in digestive organs. Indeed, gastric cancer remains the third leading cause of cancer death in men and the fifth in women, and colorectal cancer is the third most commonly diagnosed cancer in men and the second most in women world-wide 17 . In addition, hepatocellular carcinoma (HCC) is one of the most frequent malignancies and its incidence is increasing not only in an endemic area for the hepatitis virus but also in the United States and other western countries 18 . Digestive organs cover a large part of the body surface in contact with the outer environment. Accordingly, they are not only inhabited by many microorganisms but also exposed to ingested food or chemical agents, and therefore infiltrated by many immune cells in pathological as well as normal conditions, supporting the perpetuation of chronic inflammation. Therefore, it is reasonable that many cancers in digestive organs are associated with inflammation.
The best examples of inflammation-associated cancer in humans are gastric cancer and HCC. Since the discovery of H. pylori by Warren and Marshall in 1982 19 , it has been well established that H. pylori-positive patients with chronic gastritis have a significantly higher risk for gastric cancer than H. pylori-negative subjects 20 , and moreover, careful investigations have shown more than 95% positivity for H. pylori infection in gastric cancer patients 21 . On the other hand, hepatitis B virus (HBV) and HCV infections account for approximately 60% and 33% of the total HCC cases in developing countries and 23% and 20% in developed countries, respectively 6, 22 , and the majority of HCCs develop in patients who have chronic hepatitis or liver cirrhosis.
Other inflammation-associated cancers in digestive organs are colitic cancers developed in patients with inflammatory bowel disease (IBD) or celiac disease [23] [24] [25] , primary sclerosing cholangitis (PSC)-associated cholangiocarcinoma 26 , primary biliary cirrhosis-associated HCC 27 , and Barrett's cancer developed in patients with reflux esophagitis 28 . In addition, the incidence of pancreatic cancer in patients with chronic pancreatitis is reported to be 4-8 times higher than in the general population 29 , and more strikingly, the incidence of pancreatic cancer in patients with hereditary pancreatitis is 53 times higher than in the normal population 30 , indicating that chronic pancreatitis is a risk for pancreatic cancer.
In addition to cancers, inflammation is also a risk for developing various lymphomas in digestive organs. These include H. pylori-induced mucosa-associated lymphatic tissue (MALT) lymphoma or plasmacytoma 31, 32 , HCV-related lymphoma 33 , and lymphoma related to celiac disease 34 .
Mechanisms for Inflammation-Associated Cancer Development
The inflammatory response is coordinated by a large range of mediators, which are released from immune cells, mesenchymal cells and epithelial cells; these mediators exert various functions in maintaining or resolving inflammation, and at the same time are involved in cancer development. Among the mediators, cytokines play central roles in diversifying the inflammatory process, and interleukin (IL)-1β, tumor necrosis factor (TNF)-α , and IL-6 are known to be the major cytokines important for inflammation and cancer development [35] [36] [37] .
IL1-β and TNF-α act directly on epithelial cells to induce activation of transcription factor nuclear factor-κB (NF-κB), a key transcription factor mediating inflammation and cancer development 36, 37 . NF-κB activation not only promotes growth or suppresses apoptosis of epithelial cells but also stimulates the production of growth factors and cytokines such as epidermal growth factor (EGF) and IL-6, enhances cyclooxygenase (COX)2 induction, and increases ROS production 38 . The induced COX-2 subsequently has many functions, including enhancement of cell growth and angiogenesis 39 . ROS modifies protein function 40 . IL-6 activates signal transducer and activator of transcription 3 (STAT3) and thereby enhances cell growth, and stimulates growth factor production, including the Reg protein 41 . Interestingly, TNF-α and IL-6 often create a positive-feedback loop during cancer development 42 .
At the same time, these cytokines also activate mitogen-activated protein kinase (MAPK) cascades. For instance, TNF-α and IL-6 have been shown to activate the extracellular signal-regulated kinase (ERK)/MAPK cascade, an important signaling pathway involved in many processes in carcinogenesis including cell proliferation, migration, and angiogenesis 43, 44 . Similarly, IL1-β, TNF-α, and IL-6 all activate c-Jun N-terminal kinase (JNK). Although JNKs are primarily attributed to proapoptotic cell death or tumor suppression in response to inflammation or various stressors 45 , JNK activation, particularly JNK1, by proinflammatory cytokines has been reported to contribute to inflammation-associated cancer development through cell death-induced "compensatory proliferation" [45] [46] [47] [48] . In this regard, an interesting thing to note is that H. pylori directly activates ERK/MAPK and JNK in human gastric cells via a type IV secretion system-dependent mechanism 49, 50 .
Thus, these mediators of inflammation form a complex of regulatory networks, and appear to work in concert to enhance cancer development. However, for normal cells to be eventually transformed and become cancer cells with clonal expansion, inflammation has to damage cellular DNA, either genetically or epigenetically, leading to permanent alteration within the genome.
Inflammation and Genetic Modulation
Cancer is a genetic disease resulting from stepwise accumulation of genetic and epigenetic alterations that drives the progressive transformation of normal cells into malignant derivatives 51 . Inactivation of tumor-suppressor genes and/or activation of oncogenes caused by somatic mutations, DNA copy number changes, or chromosomal aberrations are widely detectable in human cancer cells. Among them, the tumor suppressor TP53 gene is one of the most frequent targets for genetic alterations in many human cancers 52 . An important point to note is that TP53 mutations are frequently present also in non-cancerous tissues with chronic inflammation before cancer development. Indeed, multiple genetic changes in the TP53 gene have been detected in various inflammatory tissues such as IBD 53, 54 , Barrett's esophagus 55 and HCV-associated chronic hepatitis 56 . For example, by analyzing the individual crypt mutation burden across plaques of the dysplasia, it was shown that mutations in TP53 genes could be identified in the majority of inflamed crypts of patients with ulcerative colitis (UC) 57 . Moreover, TP53 mutations are detectable at the frequencies of 4-15 nucleotides out of 10 4 nucleotides in the hepatocytes of the patients with chronic HCV infecction 56 . Normal mutation rates cannot account for such abundant genetic changes that accumulate in inflamed epithelial cells, suggesting that certain molecular mechanisms underlie such a large number of genetic alterations. Therefore, to understand the mechanisms of inflammation-associated tumorigenesis, several possible intrinsic mutagens responsible for genetic aberrations in the inflammatory condition have been proposed. Among them, free radicals and intrinsic DNA mutator enzymes appear to be important candidates in the setting of chronic inflammation ( Figure 1 ).
Free radicals refer to any molecular species with one or more unpaired electron(s), including ROS and RNS 38 . Interestingly, increases in TP53 gene mutations at codons 247 and 248 are paralleled by an enhanced expression of nitric oxide synthase (iNOS) in the inflamed lesions of the colonic tissues of patients with ulcerative colitis 54 . HCV infection also induces iNOS mRNA expression, thereby enhancing nitric oxide (NO) production, which in turn results in DNA breaks and enhanced mutation frequencies 58 .
Moreover, an increased level of NO accelerated spontaneous tumor development, mostly lymphomas, in Trp53-deficient mouse model infected with Cryptosporidium parvum 59 .
In the inflammatory condition, cellular ROS levels are substantially elevated, and nucleic acids exposed to ROS generate various modified bases such as oxidatively altered purines and pyrimidines 60 . These modified nucleic acids could induce the putative DNA damage, including single-or double-stranded DNA breaks, DNA intrastrand adducts, and DNA protein crosslinks 61 . In addition, ROS alters the mismatch repair function and allows mutations to accumulate in microsatellite sequences 62 . It has been well recognized that oncogene activation is capable of inducing genomic instability in precancerous lesions as well as cancer cells 63 . In this regard, ROS is also a a putative mediators that links excessive activity of oncogene products and DNA damage. For example, oncogene c-MYC overexpression results in DNA damage prior to the S phase in association with the ROS induction in normal human fibroblasts 64 .
These findings suggested that the cumulative situation of ROS production, a condition of so-called oxidative stress, is involved in both the initiation and progression of inflammation-associated cancers through the induction of genetic instability. Importantly, the typical mutation pattern induced by oxidative stress cannot account for a mutation signature observed in many human cancer tissues, particularly in inflammation-associated cancers. Among the oxidized nucleosides, one of the common products of free radical attack on DNA is 8-hydroxydeoxyguanine (8-OHdG), which is considered to be a biomarker of oxidative stress 65 . The typical pattern of nucleotide alterations induced by 8-OHdG is guanine (G)/cytosine (C) to thymine (T)/adenine (A) transversions, which have been observed in the RAS oncogene and TP53 tumor suppressor gene in lung and liver cancers 66, 67 . However, recent genome wide analyses clearly demonstrated that G/C to T/A transversions account for a minor proportion of the total mutations identified in human cancer cells, and instead C/G to T/A transitions are the most prevalent mutation pattern in various cancer tissues, including inflammation-associated cancers 68 . Thus, it appears reasonable to assume that there is an alternative mechanism that accounts for the most frequent mutational pattern, C/G to T/A transitions, detected in many human cancer tissues.
Recently, several human enzymes that are capable of inducing nucleotide alterations have been identified, providing a new avenue for understanding mutagenesis mechanisms 69 . Among them, activation-induced cytidine deaminase (AID) is a well defined molecule involved in DNA mutations in the human genome. Through its enzymatic activity, AID can deaminate C on target DNA to produce a uracil (U), and therefore turns a DNA C:G pair into a U:G mismatch. When DNA replication starts before recognition by the repair system, a U:G mismatch gives rise to C/G to T/A transition. Alternatively, recognition of a U:G mismatch by uracil-DNA-glycosylase (UNG) or mutS homolog 2 (MSH2)/mutS homolog 6 (MSH6) heterodimer induces mutations in the U:G mismatch or at the nearby A:T site ( Figure 2 ). As a result, AID can induce any type of mutations 70 . Under physiological conditions, AID contributes to generating antibody gene diversification in activated B lymphocytes by inducing somatic hypermutation and class switch recombination of immunoglobulin gene 71 . In sharp contrast to the favorable function of AID in the immune system, the role of AID in tumorigenesis through induction of genetic instability was first suggested in hematopoietic malignancies. A number of studies have demonstrated that increased AID expression in various neoplasms of the B lymphocytic lineage was associated with unfavorable mutations and chromosomal translocations 72, 73 . For instance, AID has been shown to be responsible for the chromosomal breaks in c-MYC leading to a c-MYC/immunoglobulin H (IGH) translocation in B cell lymphoma 74 . Moreover, AID induces breakpoint cluster region (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1) mutations leading to Imatinib resistance in chronic myeloid leukemia cells 75 . Since the target of AID-mediated genotoxic effects was not restricted to immunoglobulin genes and a variety of other genes also received the AID-mediated mutations in B cells 70 , it was not surprising that aberrant upregulation of AID induced genetic alterations in various tumor-related genes, leading to the transformation of hematopoietic cells.
As described, activation of NF-κB is induced in response to various inflammatory stimulations, and is deeply involved in multiple processes of cancer initiation and progression 36 . Interestingly, NF-κB is a major transcription factor for AID in B cells that is activated through cluster of differentiation 40-TNF receptor superfamily member 5 (CD40) ligation by T cells 76 , suggesting that AID might link NF-κB activation and genetic instability in non-lymphoid cells in the setting of inflammation. In agreement with this hypothesis, AID expression is induced in response to proinflammatory cytokine stimulation via the NF-κB-dependent pathway in various epithelial cells ( Figure 3 ). In hepatocytes, AID expression is induced by TNF-α through the I-κB kinase (IKK)-dependent NF-κB signaling pathway 77 . Consistent with a previous finding that the HCV core protein triggers the activation of NF-κB in hepatocytes 78 , the HCV core protein itself also up-regulates endogenous AID in cultured hepatocytes 77 .
NF-κB-mediated induction of AID expression is not limited to hepatocytes. In human gastric epithelial cells, AID expression is induced by TNF-α stimulation via activation of NF-κB, but not detected in non-stimulated cells 79 . More interestingly, aberrant AID expression is induced by the infection of a pathogenic H. pylori strain, the cytotoxin-associated gene pathogenicity island (CagPAI)-positive strain that is capable of introducing bacterial virulence factors into the host cells through a type-IV secretion system and activating NF-κB, indicating that both bacterial factors introduced into epithelial cells and the inflammatory mediators such as TNF-α and IL-1β induced by H. pylori infection cooperatively promote aberrant AID expression in H. pylori-infected gastric mucosal cells. Similar to hepatocytes and gastric mucosal cells, TNF-α stimulation resulted in upregulation of endogenous AID in human colonic cells via the IKK-dependent NF-κB signaling pathway 80 . In addition, IL-4 and IL-13, which are involved in Th2 type immune response in IBD, induced aberrant AID expression in a signal transducer and activator of transcription 6 (STAT6)-dependent manner in human colonic epithelial cells 80 . Of note, IL-4 is known to induce AID also in B cells 71 .
Consistent with the in vitro analyses, aberrant AID expression is widely detectable in not only various inflammation-associated cancer tissues but also in a variety of inflamed epithelial tissues where tumorigenic risk is high, including chronic hepatitis and cirrhosis caused by HCV infection 56 , chronic gastritis caused by H. pylori infection 79 , IBD 80 , PSC 81 , and the columnar cell-lined Barrett's esophagus 82 .
The impact of AID expression in non-lymphoid epithelial cells was clarified using both in vivo and in vitro systems with aberrant AID expression. Constitutive and ubiquitous AID expression in transgenic mice induced lymphoma development via the accumulation of somatic mutations in various non-immunoglobulin genes, including the proto-oncogene c-Myc 83 . More importantly, further phenotypic analyses revealed that AID transgenic mice also develop neoplasia in epithelial tissues, including lung, liver and stomach accompanied by the emergence of Trp53 mutations, indicating that aberrant AID expression in epithelial cells can induce genetic instability leading to cancer development 83, 84 . It is widely recognized that the frequently mutated tumor-related genes differ among different cancers. For instance, nucleotide alterations in the K-RAS are detectable in almost all human pancreatic cancers 85 , while it is relatively low in other human tumors. Similarly, the c-MYC is a frequent target for genetic alterations in human lung cancers, while its nucleotide alterations are rare in hepatocellular carcinoma 86 . However, the mechanisms underlying the accumulation of organ-specific genomic changes in oncogenic pathways are not well known.
Interestingly, organ-specific changes in mutational profiles were observed in the epithelial tissues of the AID transgenic mice. Indeed, the c-Myc gene was frequently mutated in non-cancerous tissue of the lung, while K-ras gene mutations were frequently detectable in gastric cancer developed in AID transgenic mice 84 . Thus, the organ-specific differences in the mutational profiles in AID transgenic mice suggest the possibility that the target preference of AID-induced mutagenesis in different tissues might contribute to the diversity of tissue-specific oncogenic pathways in various epithelial organs.
In vitro analyses using human cultured cells with constitutive AID expression revealed that TP53 mutations were frequently induced by AID genotoxic activity in hepatocytes, and gastric, colonic, and bile duct epithelial cells 77, [79] [80] [81] . Similar to the TP53 gene, the cyclin-dependent kinase inhibitor (CDKN)-2B-CDKN2A locus was identified as a target for AID-mediated genotoxic activity. The CDKN2B-CDKN2A locus encodes the potent suppressor proteins, p16 INK4a , p15 INK4b , and p14 ARF , that regulate the activities of the retinoblastoma protein (RB) and the TP53 transcription factor. Aberrant AID expression preferentially induces somatic mutations at the CDKN2B-CDKN2A locus in gastric epithelial cells and biliary cells 81, 87 . Moreover, comparative genomic hybridization analysis clearly demonstrated that constitutive AID activation in cultured gastric epithelial cells caused submicroscopic deletions as represented by copy number losses of various chromosomal loci, especially at the CDKN2B-CDKN2A locus at 9p21. Copy number reduction of Cdkn2b-Cdkn2a was also seen in the gastric mucosa of AID transgenic mice 87 . In agreement with the preferential deletions at the CDKN2B-CDKN2A locus in gastric epithelial cells by AID introduction, AID expression was required for inducing DNA single-strand breaks in the CDKN2B gene in leukemia cells 88 , and furthermore, the deletion of the CDKN2B-CDKN2A locus is frequently detectable in AID-expressing lymphoid blast crisis leukemia cells 75 . These findings suggest that AID can induce both mutations and deletions at the same gene locus, and moreover, that the representative tumor-suppressor genes, TP53 and CDKN2B-CDKN2A may be common targets for AID-mediated genotoxic effects in various human tissues in the setting of inflammation.
Finally, a recent finding that a deficiency of endogenous AID reduced the incidence of both accumulation of somatic mutations in the Trp53 gene and the development of colitis-associated colorectal cancers further supports the critical role of AID in inflammation-associated cancer development via its ability to induce genetic alterations in tumor-related genes 89 .
Inflammation and Epigenetic Modulation
Epigenetic modifications are DNA-associated modifications that are inherited upon somatic cell replication, which include DNA methylation and histone modifications 90 .
Coordinated changes of epigenetic modifications control development and tissue differentiation, and erasure of epigenetic modifications is involved in reprogramming.
In somatic cells, DNA methylation is present in repetitive elements, CpG-sparse regions, and in a very limited number of CpG islands 91, 92 . DNA methylation of a CpG island in a promoter region causes silencing of its downstream gene, whether it is a protein-coding gene or a miRNA gene, by forming nucleosomes and thus possibly blocking access of RNA polymerase II to the promoter 93, 94 . In contrast, DNA methylation of a gene body is often associated with increased gene expression 91, 95 .
Histone modifications denote chemical modifications, such as acetylation, methylation, and ubiquitination of lysine and arginine residues of histones, mainly H3 and H4 but also H2A and H2B 93 In cancer cells, the presence of regional hypermethylation and global hypomethylation has been described 98, 99 . Regional hypermethylation refers to aberrant DNA methylation of promoter CpG islands physiologically kept unmethylated 95, 100 . If aberrant methylation is induced in a promoter CpG island, it consistently induces silencing of its downstream gene 90 . Many tumor-suppressor genes that have promoter CpG islands, such as CDKN2A, mutL homolog 1 (MLH1), cadherin-1 (CDH1), and RAS-association domain family 1, isoform A (RASSF1A), can be permanently inactivated by aberrant DNA methylation as drivers, that have significant roles in cancer development. At the same time, most of the aberrant DNA methylation of promoter CpG islands are considered to be passengers, that play no role in carcinogenesis 14 .
Several hundreds to thousands of promoter CpG islands are aberrantly methylated in a cancer, and the number is too large for all of them to be drivers. Moreover, most of the genes methylated in cancers are not expressed in normal tissues 101, 102 , and such genes are considered to be not involved in carcinogenesis. Global hypomethylation was shown to be causally involved in carcinogenesis by inducing genomic instability 103 . In addition, induction of H3K27 me3 is considered to be an alternative mechanism to induce gene silencing 96 , and aberrant H3K27 me3 was observed in promoter regions consisting of 200-600 genes 96, 104 . Again, the number is very large, and most are expected to be passengers.
As inducers of aberrant DNA methylation, aging was first indicated 105 , and chronic inflammation was then suggested by the presence of aberrant DNA methylation of specific tumor-suppressor genes in non-cancerous colonic mucosae of patients with IBD 106, 107 . Aberrant DNA methylation was present more frequently in liver tissues of patients with HCC than in those with metastatic liver tumors 108 . By measuring methylation levels of passenger genes in gastric mucosae of H. pylori-infected individuals, a very close association between H. pylori infection and high methylation levels in gastric mucosa was demonstrated 15 . Aberrant DNA methylation is particularly prominent in chronic inflammation-associated cancers, such as gastric cancer, HCCs, colitic cancer, cholangiocarcinoma, Barrett's cancer, and pancreatic cancer 13 . These findings strongly indicated that the major inducer of aberrant DNA methylation is chronic inflammation.
Levels of aberrant DNA methylation accumulated in normal-appearing tissues correlate with the risk of gastric, colon, breast, and renal cancers 15, [109] [110] [111] [112] . Such accumulation mainly involves passenger and driver genes to some extent, and is considered to form an epigenetic field for cancerization (epigenetic field defect) ( Figure  4 ) 113 . Chronic inflammation-associated cancers are known to show multiple events, which can be explained by the presence of a field defect in normal-appearing tissues.
Along with the accumulation of genetic alterations, an epigenetic field defect is deeply involved in the development of inflammation-associated cancers. The degree of epigenetic field defect can be easily measured using methylation levels of marker genes 114 , which are passenger genes in most cases and show relatively high methylation levels in predisposed tissues 113 .
Mechanistic studies, including cause and effect of accumulated aberrant DNA methylation and chronic inflammation, were conducted using animal models. When H.
pylori-induced inflammation was suppressed by cyclosporine A in Mongolian gerbils, induction of aberrant DNA methylation was markedly suppressed, while the number of H. pylori in gastric mucosae was unaffected 16 . This indicated that inflammation, not H. promoter was associated with not only gastric cancer susceptibility 35 , but also the presence of the CpG island methylation phenotype in gastric cancers 116 .
Another animal model for methylation induction by chronic inflammation is mouse colitis induced by administration of dextran sulfate sodium (DSS) 117 . Aberrant DNA methylation of multiple genes occurred in DSS-induced colitis mucosae before induction of colon tumors, showing an epigenetic field 118 . The induction of aberrant DNA methylation was unaffected even in severe combined immunodeficiency (SCID) mice that lacked T and B cells, suggesting that infiltrated macrophages might be critical for methylation induction. Gene expression analysis in colonic mucosae in wild-type and SCID mice showed that expression levels of Il1b, Nos, and Ifng were associated with methylation induction in colonic mucosae. Taken together with the finding in the H.
pylori-infected gerbils, infiltration of macrophages and resulting secretion of Il-1β and
Tnf-α as well as production of active oxygen species are believed to be involved in induction of aberrant DNA methylation in epithelial cells (Figure 1) .
Several in vitro studies have been conducted to examine inflammatory signals that lead to methylation induction in target cells. Treatment of insulinoma or blood cells with
IL-1β or a NO donor induced methylation of endogenous genes by increasing activity of DNA methyltransferase(s) (DNMTs) 119 . IL-6 induces DNMT1 transcription by increasing its promoter activity and suppressing miR-148a and miR-152, both of which target DNMT1 120,121. Although some studies suggested that DNA methylation is induced by IL-1β or IL-6, the changes were marginal possibly because identification of appropriate target CpG islands was difficult and the levels of increase were too small to be detected by ordinary methods. Prostaglandin E2 treatment of cancer cell lines increased DNMT1 and DNMT3B expression, and induced DNA methylation of specific genes, which was also observed in vivo 122 .
In contrast to in vitro studies, mRNA expression levels of Dnmt1, Dnmt3A, and Dnmt3B were not increased in vivo, such as colonic mucosae with DSS-induced colitis 16 , and human gastric tissues with H. pylori infection 123 101, 102 .
Taken together, we can hypothesize a model for aberrant DNA methylation induction in vivo ( Figure 5 ). Inflammatory signals mainly from macrophages, such as IL-1β, TNF-α, and IL-6, and oxidative stress, possibly produced by NO synthase, are likely to recruit a complex with DNMT1 and EZH2 to promoter CpG islands with H3K27 me3 flag and without protection by RNA polymerase II. Since DNA methylation is harmful to a gene, aberrant DNA methylation is likely to be induced only rarely and at scattered CpG sites within a CpG island (seeds of methylation) 123 . Most "seeds of methylation" are erased during cell replication, but can lead to dense methylation of a CpG island at very low frequencies 125, 126 . If such dense methylation is induced in a promoter CpG island of a tumor-suppressor gene, the tissue becomes predisposed to carcinogenesis, and forms an epigenetic field defect.
In addition to aberrant DNA methylation of promoter CpG islands, cancer cells are characterized by global DNA hypomethylation as well as aberrant hypomethylation of oncogenes 99, 127 . Gastric mucosa infected by H. pylori displays global hypomethylation 128 . In this regard, it is interesting to note that AID has been recently shown to be involved in active DNA demethylation during fetal development 129 .
Mechanistically, AID deaminates 5-methyl cytosine (5-mC) to yield T. This T would be subsequently removed by either of the T:G mismatch-specific glycosylases, thymidine DNA glycosylase or methyl-CpG binding domain protein 4 (MBD4). The resulting abasic site would then be replaced by an unmethylated C via base excision repair processes, resulting in DNA demethylation. Notably, AID participates in active demethylation by 5-mC hydroxylase, ten-eleven translocation 1 (TET1), and subsequent gene expression in the dentate gyrus of adult mouse brain 130 . Thus, whether AID is involved in DNA demethylation during cancer development is an interesting topic for future studies 131 . The fact that AID targets the chromatin marked by H3K4 me3 histone modification 132 , in contrast to preferential DNA methylation at promoter CpG islands with H3K27 me3 histone modification 101, 102 , might suggest opposing mechanisms for induction of DNA methylation and demethylation.
Inflammation and MicroRNA Modulation
MicroRNAs (miRNAs) are short noncoding RNAs that regulate the expression of many target genes post-transcriptionally, and are thus involved in a variety of cellular functions. Recent studies have revealed that miRNAs have important roles in cancer development as either oncogenes or tumor suppressor genes by regulating various cancer-related proteins or mRNA expressions 133, 134 . Indeed, cancer cells are associated with dysregulation of many miRNA expressions, which occurs through a variety of mechanisms, such as genetic changes, epigenetic regulation, or altered expression of transcription factors 135 . On the other hand, miRNA expression is also altered in inflammatory conditions, and such alterations in miRNA expression appear to play roles not only in controlling chronic inflammation, but also in promoting cancer development 136, 137 . Many of the changes in miRNA expressions observed in inflammatory tissues are derived from immune cells that may participate in hematopoietic tumorigenesis 138 . However, recent reports have shown that inflammation also induces changes in cancer-related miRNAs in epithelial cells, suggesting a direct link between alteration of miRNA expressions and inflammation-associated cancer development 139, 140 .
miRNA expressions in epithelial cells can be altered during inflammation through various mechanisms such as NF-κB activation by toll-like receptors (TLRs) or cytokine stimulation and STAT3 phosphorylation by IL-6 or other cytokines [139] [140] [141] [142] [143] .
Among those, several miRNAs are identified as tumor suppressor miRNAs. miR-7
targets not only Egfr but also latrophilin (Lphn2), brain abundant, membrane attached signal protein 1 (Basp1) and musculoaponeurotic fibrosarcoma oncogene homolog (Mafg), and thus is considered to be a tumor suppressor miRNA 142 . In a mouse model of inflammation-associated cancer development, expression of miR-7 has been shown to be inhibited by activated macrophages in Helicobacter-infected gastritis mucosa, being involved in gastric cancer development, whereas it was increased in germ-free conditions 142 . Lethal-7 (Let-7), consisting of 12 members, targets the RAS family and c-MYC 144, 145 , and genomic locations of let-7 family members are frequently deleted in colon cancers and other solid cancers 146 . NF-κ B activation enhances Lin28B transcription that causes posttranscriptional inhibition of let7 family member expression, and let-7 directly inhibits IL-6 expression, a cytokine often produced in cancer cells.
Thus, reduction of let-7 expression by NF-κB activation appears to play a role in a positive feedback loop for NF-κB activation through an increase of IL-6 in cancer cells 147 .
miR-155, a possible oncogenic miRNA, is involved in blood cell maturation, immune responses and autoimmune disorders, and high expression of miR-155 is associated with the development of myeloproliferative disorders 148 . Recent studies have revealed a direct link between elevation of miR-155 and tumor formation and development in gastric and colon cancers 148, 149 . miR-155 expression is induced by NFκ B, IFN-β and TLR stimulation 150 , and thus enhanced by H. pylori and lipopolysaccharadie (LPS) treatment 151 . Recently, Croce et al. 143 reported that TNF-α/LPS stimulation enhances miR-155 expression in association with an increased mutation rate. They also showed that miR-155 targets mitosis inhibitor protein kinase 1 (WEE1), which blocks cell-cycle progression, and therefore reasoned that reduction of WEE1 by miR-155 allowed cell division to continue even in the presence of DNA damage, leading to enhanced mutation induction. In another study, they also demonstrated that miR-155 promotes gene mutations by down-regulating the core mismatch repair proteins, hMSH2, hMSH6 and hMLH1 152 . Of particular interest are the recent reports showing that miR-155 negatively regulates AID in B cells. Teng et al. 153 demonstrated that miR-155 is upregulated in B cells undergoing class-switch recombination, and regulates the germinal center reaction by modulating AID.
Moreover, miR-155 has been suggested to inhibit MYC-IGH translocation by reducing AID mRNA and protein in B cells 154 . Thus, although an inhibitory effect of miR-155 on AID has not been examined in non-B cells, miR-155 may also have a tumor suppressor function in epithelial cells by inhibiting AID production.
A miRNA expression pattern distinct from normal colonic mucosa has been found in the colonic mucosa and colitic tumor of patients with IBD as well as mice with colonic inflammation, including upregulation of miR-21 and miR-3 155 . miR-21 is one of the most highly expressed miRNAs in colonic tissues of patients with ulcerative colitis 155 , and its expression is enhanced by LPS and IL-6 through STAT3 activation,
targeting key regulators of cell proliferation and apoptosis such as phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) 156 . Olaru et al. 157 recently demonstrated that in colitic cancer development miR-31 expression increases in a stepwise fashion from IBD to cancer, and that miR-31 directly targets regulating factor inhibiting hypoxia inducible factor 1 (FIH-1), decreasing its repressor activity for hypoxia-inducible factor 1 (HIF-1).
It is now evident that miRNAs exert various functions in inflammation-associated cancer development. However, alterations of miRNA expression observed in inflammatory tissues occur in both immune cells and epithelial cells. Accordingly, it is important to dissect miRNA changes in the two cell types, as the patterns of the miRNA changes are different between immune cells and epithelial cells. Further elucidation of the changes of miRNA expression, particularly in epithelial cells, will facilitate our understanding of the role of tumor-related miRNAs in inflammation-associated cancer development.
Application to Cancer Prevention, Diagnostics, and Therapeutics
In order to prevent inflammation-associated cancer development, it is crucial to cure or control inflammation. Indeed, it has been repeatedly demonstrated that long-term therapy with anti-inflammatory drugs resulted in fewer appearances of tumors 158 . The best way to control chronic inflammation is, of course, to eliminate causative infections. In other cases unrelated to infection such as IBD and PSC, one approach is to block the action of key regulators of inflammation. In this regard, NF-κ B or STAT3, and their activators TNF-α or IL-6, respectively, may be good targets for suppressing the inflammatory response. However, since treatment usually needs to be continued for long periods to control chronic inflammation, agents without serious side effects with lower costs should be developed. For this purpose, many natural agents derived from vegetables, fruits, spices, and their components have been tested. Among them, curcumin, derived from yellow spice turmeric (Curcuma longa) has been used for centuries, and has been shown to suppress NF-κB-as well as STAT3-regulated inflammation 159 , and thus can be administered safely over the long-term 160 . Indeed, a recent study showed that curcumin reduced TNF-α expression, prevented cancer-associated weight loss, and induced apoptosis of tumors in patients with colorectal cancer 161 . Resveratrol, a natural polyphenolic, non-flavonoid antioxidant found in grapes and other berries has been shown to have generalized inhibitory effects on inflammation-related molecules such as NF-κB, COX2 and tyrosine kinases 162 .
Recently, Resveratrol was found to alter the expression of many tumor-related miRNAs 163 . Similar types of agents may have the potential to both prevent and treat cancers 164 .
In contrast to controlling inflammatory mediators, blocking genetic modulation appears to be difficult. One might consider inhibiting AID. However, because AID plays a critical role in immunoglobulin maturation in B cells, specific targeting for AID in the epithelial cells without affecting AID in B cells is critical. Control of epigenetic modulation can be considered from two aspects: suppression of methylation induction and reversal of induced methylation. Since induction of methylation is not essential in adult somatic cells, control of this process is a promising approach to prevent chronic inflammation-associated cancers. On the other hand, reversal of aberrant DNA methylation is an attractive idea to repair an epigenetic field defect, but targeting only aberrant DNA methylation without affecting physiological DNA methylation is currently very difficult.
H. pylori eradication ameliorates chronic inflammation, and reduces the risk for gastric cancer. However, it is apparent that eradication cannot completely resolve chronic inflammation, as some patients develop gastric cancer even after successful eradication 165 . Likewise, some patients with chronic hepatitis or liver cirrhosis due to HCV infection also develop HCC after obtaining sustained virological response (SVR) 166 . As such, when inflammation is not appropriately controlled or even when inflammation is resolved after long-standing inflammation, accurate prediction for the risk of developing cancers in the inflammatory tissues becomes important. As was discussed, carcinogenesis is characterized by a stepwise accumulation of both genetic and epigenetic changes. Importantly, previous data suggested that the extent of those genetic and epigenetic modulations is paralleled with duration or severity of inflammation 15, 167 , and the degree of epigenetic field defect can be measured relatively easily and accurately. Thus, both qualitative and quantitative detection of these genetic and epigenetic changes in inflammatory tissues or tissues previously exposed to inflammation may provide a good risk marker for inflammation-associated cancer development. Indeed, epigenetic risk markers that can differentiate gastric mucosae of cancer patients from those of healthy individuals with odds ratios between 12.7-36.0 have been isolated 168, 169 , and a prospective study is now being conducted. 
Conclusion

